Trial reportThe Journal of allergy and clinical immunology2020
Baseline sputum eosinophil + neutrophil subgroups' clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort.
Open access · bronzeAbstract readClinical TrialLetterMulticenter Study
In one paragraph
Trial report in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 38 citations in OpenAlex.
- Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils.Journal of immunology research · 2023Trial
- NLRP3-mediated epithelial pyroptosis involved in airway hyperresponsiveness in combined eosinophilic and neutrophilic asthma.Cell communication and signaling : CCS · 2026Article
- Profile of mild/moderate asthma patients: Baseline data from the MANI cohort.The World Allergy Organization journal · 2025Article
- T1-T2 Interplay in the Complex Immune Landscape of Severe Asthma.Immunological reviews · 2025Review
- Biologic Medications for Severe Asthma: Implications for Understanding Pathogenic Heterogeneity and Endotypes.Annual review of medicine · 2025Review
- In mouse model of mixed granulocytic asthma with corticosteroid refractoriness, Bronchom mitigates airway hyperresponsiveness, inflammation and airway remodeling.Molecular medicine (Cambridge, Mass.) · 2024Article
- The impact of inflammatory cells on lung function in asthmatics in a cross sectional retrospect study.Heliyon · 2024Article
- Sex-specific alterations in the gut and lung microbiome of allergen-induced mice.Frontiers in allergy · 2024Article
- Investigations of a combination of atopic status and age of asthma onset identify asthma subphenotypes.The Journal of asthma : official journal of the Association for the Care of Asthma · 2023Article
- Low CC16 mRNA Expression Levels in Bronchial Epithelial Cells Are Associated with Asthma Severity.American journal of respiratory and critical care medicine · 2023Article
- Approaches to Management of Asthma: Guidelines for Stepped Care and Self-Monitoring.Advances in experimental medicine and biology · 2023Article
- Urinary total conjugated 3-bromotyrosine, asthma severity, and exacerbation risk.American journal of physiology. Lung cellular and molecular physiology · 2022Article
- Review
- Neutrophils and Asthma.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- Article
- Ketamine Attenuates Airway Inflammation via Inducing Inflammatory Cells Apoptosis and Activating Nrf2 Pathway in a Mixed-Granulocytic Murine Asthma Model.Drug design, development and therapy · 2022Article
- Narrative Review: how long should patients with cough variant asthma or non-asthmatic eosinophilic bronchitis be treated?Journal of thoracic disease · 2021Review
- Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research Program.American journal of respiratory and critical care medicine · 2021Article
- Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes.American journal of respiratory and critical care medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 1 country.
Annette T HastieWake Forest University School of Medicine, Winston-Salem, NC. Electronic address: ahastie@wakehealth.edu.
David T MaugerPenn State College of Medicine, Hershey, Pa.
Loren C DenlingerUniversity of Wisconsin-Madison, Madison, Wis.
Andrea CoverstoneWashington University School of Medicine, St Louis, Mo.
Mario CastroWashington University School of Medicine, St Louis, Mo.
Serpil ErzurumCleveland Clinic, Cleveland, Ohio.
Nijar JarjourUniversity of Wisconsin-Madison, Madison, Wis.
Bruce D LevyBrigham and Womens Hospital, Boston, Mass.
Deborah A MeyersUniversity of Arizona College of Medicine, Tucson, Ariz.
Wendy C MooreWake Forest University School of Medicine, Winston-Salem, NC.
Brenda PhillipsPenn State College of Medicine, Hershey, Pa.
Sally E WenzelUniversity of Pittsburgh, Pittsburgh, Pa.
John V FahyUniversity of California San Francisco, Calif.
Elliot IsraelBrigham and Womens Hospital, Boston, Mass.
Eugene R BleeckerUniversity of Arizona College of Medicine, Tucson, Ariz.
NHLBI SARP 3 Investigators
University of Arizona · USBrigham and Women's Hospital · USPenn State Milton S. Hershey Medical Center · USUniversity of California, San Francisco · USUniversity of Wisconsin–Madison · USWake Forest University · USWashington University in St. Louis · USCleveland Clinic · USUniversity of Pittsburgh · US
Funding
Rapid saliva antigen test for SARS-CoV-2 detectionU01HL146002 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ARONICA, MARK A, CASTRO, MARIO · 2019 to 2023
$17.3MClinical Coordinating Center for the Severe Asthma Research Program (SARP)U10HL109086 · NHLBI · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MAUGER, DAVID T. · 2011 to 2017
$8.1MSpecialized Pro-Resolving Mediators in AsthmaR01HL122531 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI LEVY, BRUCE D · 2014 to 2024
$4.7MAMSA: ALXR/FBR Mediated Signaling in Severe AsthmaU10HL109172 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ISRAEL, ELLIOT, LEVY, BRUCE D · 2011 to 2016
$4.2MAirway redox biochemistry as a deteriminant of asthma phenotype during adolescen*U10HL109250 · NHLBI · UNIVERSITY OF VIRGINIA · PI ERZURUM, SERPIL C., GASTON, BENJAMIN · 2011 to 2016
$4.2MClinical and Molecular Phenotypes of Severe AsthmaU10HL109146 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2011 to 2016
$4.0MImplications and Stability of Clinical and Molecular Phenotypes of Severe AsthmaU10HL109152 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WENZEL, SALLY E · 2011 to 2016
$3.9MStability of Severe Asthma Phenotypes: Impact of ExacerbationsU10HL109168 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI JARJOUR, NIZAR N · 2011 to 2016
$3.9MSevere Asthma Research Program (SARP)-Washington UniversityU10HL109257 · NHLBI · WASHINGTON UNIVERSITY · PI CASTRO, MARIO · 2011 to 2016
$3.8MLongitudinal Phenomics and Genetics of Severe AsthmaU10HL109164 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI BLEECKER, EUGENE ROLAND, MEYERS, DEBORAH A. · 2011 to 2016
$3.8MNHLBI NIH HHS R01 HL122531NHLBI NIH HHS U01 HL146002NHLBI NIH HHS U10 HL109086NHLBI NIH HHS U10 HL109146NHLBI NIH HHS U10 HL109152NHLBI NIH HHS U10 HL109164NHLBI NIH HHS U10 HL109168NHLBI NIH HHS U10 HL109172NHLBI NIH HHS U10 HL109250NHLBI NIH HHS U10 HL109257
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAsthmaCohort StudiesEosinophilsFemaleHumansMaleMiddle AgedNeutrophilsSputum
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.